Hikma’s H2 18 top-line missed our as well as the street’s expectations marginally. Revenue was up by 4.4% to $1.09bn, driven by the robust performance by the Generic segment (+14%). A decline in the Branded segment (-1%; FX headwinds played a major role), was compensated by a marginal increase in the Injectables (+1%). On the profitability front, the EBITDA margin was up by 5.6ppt to 27%, attributable to a reduction in COGS (47.8% of sales vs 50.3% in H2 17; due to the consolidati
15 Mar 2019
Mediocre H2 amid muted FY 19 guidance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Mediocre H2 amid muted FY 19 guidance
Hikma Pharmaceuticals Plc (HIK:LON) | 1,926 0 0.0% | Mkt Cap: 4,274m
- Published:
15 Mar 2019 -
Author:
Kamla Singh -
Pages:
3
Hikma’s H2 18 top-line missed our as well as the street’s expectations marginally. Revenue was up by 4.4% to $1.09bn, driven by the robust performance by the Generic segment (+14%). A decline in the Branded segment (-1%; FX headwinds played a major role), was compensated by a marginal increase in the Injectables (+1%). On the profitability front, the EBITDA margin was up by 5.6ppt to 27%, attributable to a reduction in COGS (47.8% of sales vs 50.3% in H2 17; due to the consolidati